HIV cascade of care in Greece: Useful insights from additional stages

Background Aiming to eliminate HIV infection, UNAIDS has set a global “90-90-90” target by 2020. We sought to construct a 6-stages HIV Cascade of Care (CoC) in Greece, overall and by risk group, to assess risk-group and stage-specific progress in achieving the UNAIDS target. Patients and methods Combining data from the HIV/AIDS surveillance system and a population-based HIV cohort study, the CoC included: i) number of people living with HIV (PLHIV) by end of 2013; ii) proportion of PLHIV ever diagnosed; iii) proportion of diagnosed linked-to-care iv) proportion of linked-to-care ever initiating antiretroviral therapy (ART); v) proportion of treated who retained-in-care vi) proportion of those retained-in-care who were virally suppressed (≤200 copies/mL) at their last visit (01/07/2012-31/12/2013). Results In 2013, 14147 PLHIV were in Greece. Overall, proportions of each stage in the cascade were: 78.4% diagnosed; 86% linked-to-care; 78.5% initiated ART; 86.4% retained-in-care, and 87.1% virally suppressed. Totally, 42.6% of all PLHIV were virally suppressed. The percentage diagnosed was lower among heterosexual men and women (heterosexuals) than in MSM (men who have sex with men) or PWID (people who inject drugs). Most MSM were linked to care (97.2% of diagnosed) while a substantial proportion of PWID were not (80.8% of diagnosed). Once treated, PWID remained in care in similar proportions to MSM. Unlike PWID, a high proportion of the retained in care MSM and heterosexuals achieved viral suppression. Conclusions At the end of 2013, we identified gaps in the HIV CoC in Greece, which differed across risk groups. Targeted interventions are critical in optimizing early diagnosis and timely linkage. A 6-stage CoC, stratified by risk group, can inform strategic public health planning in improving HIV treatment outcomes.

[1]  M. Rosińska,et al.  Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population? , 2018, AIDS.

[2]  M. Fox,et al.  A new cascade of HIV care for the era of “treat all” , 2017, PLoS medicine.

[3]  Richard D Moore,et al.  Retention, Antiretroviral Therapy Use and Viral Suppression by History of Injection Drug Use Among HIV-Infected Patients in an Urban HIV Clinical Cohort , 2017, AIDS and Behavior.

[4]  A. Mocroft,et al.  Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe , 2017, AIDS.

[5]  A. d’Arminio Monforte,et al.  The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  L. Borrell,et al.  Neighborhood Characteristics Associated with Achievement and Maintenance of HIV Viral Suppression Among Persons Newly Diagnosed with HIV in New York City , 2017, AIDS and Behavior.

[7]  K. Fennie,et al.  Black–White and Country of Birth Disparities in Retention in HIV Care and Viral Suppression among Latinos with HIV in Florida, 2015 , 2017, International journal of environmental research and public health.

[8]  A. Pharris,et al.  HIV continuum of care in Europe and Central Asia , 2017, HIV medicine.

[9]  A. Sönnerborg,et al.  Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90‐90‐90 continuum of HIV care targets , 2016, HIV medicine.

[10]  A. Apisarnthanarak,et al.  Uptake of HIV testing and counseling, risk perception and linkage to HIV care among Thai university students , 2016, BMC Public Health.

[11]  Wendy Macdowall,et al.  HIV testing, risk perception, and behaviour in the British population , 2016, AIDS.

[12]  Don C Des Jarlais,et al.  Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme. , 2015, Addiction.

[13]  Ard van Sighem,et al.  Estimating HIV Incidence, Time to Diagnosis, and the Undiagnosed HIV Epidemic Using Routine Surveillance Data , 2015, Epidemiology.

[14]  S. Fernández-Balbuena,et al.  The rapid test in Spanish pharmacies: a novel programme to reach heterosexual men? , 2015, HIV medicine.

[15]  J. Dehovitz,et al.  The cascade of care in the Eastern European country of Georgia , 2015, HIV medicine.

[16]  A. Pozniak,et al.  Large disparities in HIV treatment cascades between eight European and high-income countries – analysis of break points , 2014, Journal of the International AIDS Society.

[17]  Anne M Johnson,et al.  Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE) , 2013, PLoS medicine.

[18]  T. Bärnighausen,et al.  High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa , 2013, Science.

[19]  A. Hatzakis,et al.  HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[20]  J. Steiner,et al.  The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.